Positron emission tomography in patients with breast cancer using 18F-3′-deoxy-3′-fluoro-l-thymidine (18F-FLT)—a pilot study
Authors:
- H.J. HoekstraHHH.J. Hoekstra
- A.J.H. SuurmeijerASA.J.H. Suurmeijer
- 1 February 2006
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 32 (1) , 39-43
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast CancerJournal of Clinical Oncology, 2004
- [ 18 F]FLT PET for diagnosis and staging of thoracic tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Potential impact of [ 18 F]3'-deoxy-3'-fluorothymidine versus [ 18 F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Comparison of fluorodeoxyglucose positron emission tomography and ‘conventional diagnostic procedures’ for the detection of distant metastases in breast cancer patientsNuclear Medicine Communications, 2002
- FDG uptake in breast cancer: correlation with biological and clinical prognostic parametersEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and LimitationsJournal of Clinical Oncology, 2000
- 18-FDG imaging in breast cancerSeminars in Nuclear Medicine, 1999
- Imaging proliferation in vivo with [F-18]FLT and positron emission tomographyNature Medicine, 1998
- Association between [ 18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observationEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.Radiology, 1993